CLINICAL PROOF OF PRINCIPLE AND FAVORABLE TOLERABILITY PROFILE SHOWN WITH ORALLY DOSED MORF-057 AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE UC: PHASE 2A EMERALD-1 STUDY RESULTS

Bruce E. Sands  ¹     Stefan Schreiber  ²     Silvio Danese  ³     Jaroslaw Kierkus  ⁴     Brihad Abhyankar  ⁵     Michael Choi  ⁵     Carolyn Soo  ⁵     Yujun Wu  ⁵     Fangui Sun  ⁵     Dooyoung Lee  ⁵     Dan Cui  ⁵     Cuyue Tang  ⁵     Maloy Mangada  ⁵     Ali Hussain  ⁵     Peter Linde  ⁶     Adrian Ray  ⁶     Oladele Babalola  ⁶     Sharon Brown  ⁶     Sarah Hammer  ⁶     Kerry McConie  ⁶     Bruce Rogers  ⁶     Laurent Peyrin-Biroulet  ⁷     Brian G. Feagan  ^8    
1 Icahn School of Medicine at Mount Sinai, New York, United States
² University Hospital Schleswig-Holstein, Kiel, Germany
³ Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Italy
⁴ Children’s Memorial Health Institute, Warsaw, Poland
⁵ Morphic Therapeutic, Waltham, United States
⁶ Past Employee of Morphic Therapeutic, Waltham, United States
⁷ Inserm U1256, Nancy University Hospital, Vandoeuvre-les-Nancy, France
⁸ The University of Western Ontario, London, Canada

Topic
IBD

Session
Medical therapy of IBD: Facts and challenges (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)